Cathleen Y Xing1, Michelle Doose1,2, Bo Qin2,3, Yong Lin1,2, Tiffany L Carson4, Jesse J Plascak1,2, Kitaw Demissie5, Chi-Chen Hong6, Elisa V Bandera1,2,3, Adana A M Llanos7,8. 1. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA. 2. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 3. Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ, USA. 4. Division of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA. 5. Department of Epidemiology and Biostatistics, SUNY Downstate Health Sciences University School of Public Health, Brooklyn, NY, USA. 6. Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 7. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA. Adana.Llanos@Rutgers.edu. 8. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Adana.Llanos@Rutgers.edu.
Abstract
PURPOSE: To determine the association of pre-diagnostic allostatic load (AL) with health-related quality of life (HRQOL) among Black women with breast cancer. METHODS: In a sample of 409 Black women with non-metastatic breast cancer enrolled in the Women's Circle of Health Follow-Up Study (WCHFS), two pre-diagnostic AL measures were estimated using medical records data from up to 12 months prior to breast cancer diagnosis: AL-lipid/metabolic profile-based measure and AL-inflammatory profile-based measure. HRQOL was assessed approximately 24 months post diagnosis, using the Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) instrument, including 5 subscale scores [presented by physical well-being (PWB), social & family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), and breast cancer-specific scale (BCS)] and 3 derived total scores [presented by trial outcome index (TOI), Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-B]. We used multivariable logistic regression models, using dichotomized AL scores (lower AL: 0-3 points, higher AL: 4-8 points), to assess the associations between the two pre-diagnostic AL measures and HRQOL. RESULTS: Higher pre-diagnostic AL was associated with poorer FWB and lower FACT-G, but these associations were statistically significant for the AL-inflammatory profile-based measure (FWB: OR 1.63, 95% CI 1.04, 2.56; FACT-G: OR 1.62, 95% CI 1.04, 2.54), but not the AL-lipid/metabolic profile-based measure (FWB: OR 1.45, 95% CI 0.81, 2.59; FACT-G: OR 1.33, 95% CI 0.75, 2.37). CONCLUSION: These findings suggest that higher AL, particularly when measured using the inflammatory profile-based measure, was associated with poorer HRQOL, namely FWB and FACT-G, among Black breast cancer survivors.
PURPOSE: To determine the association of pre-diagnostic allostatic load (AL) with health-related quality of life (HRQOL) among Black women with breast cancer. METHODS: In a sample of 409 Black women with non-metastatic breast cancer enrolled in the Women's Circle of Health Follow-Up Study (WCHFS), two pre-diagnostic AL measures were estimated using medical records data from up to 12 months prior to breast cancer diagnosis: AL-lipid/metabolic profile-based measure and AL-inflammatory profile-based measure. HRQOL was assessed approximately 24 months post diagnosis, using the Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) instrument, including 5 subscale scores [presented by physical well-being (PWB), social & family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), and breast cancer-specific scale (BCS)] and 3 derived total scores [presented by trial outcome index (TOI), Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-B]. We used multivariable logistic regression models, using dichotomized AL scores (lower AL: 0-3 points, higher AL: 4-8 points), to assess the associations between the two pre-diagnostic AL measures and HRQOL. RESULTS: Higher pre-diagnostic AL was associated with poorer FWB and lower FACT-G, but these associations were statistically significant for the AL-inflammatory profile-based measure (FWB: OR 1.63, 95% CI 1.04, 2.56; FACT-G: OR 1.62, 95% CI 1.04, 2.54), but not the AL-lipid/metabolic profile-based measure (FWB: OR 1.45, 95% CI 0.81, 2.59; FACT-G: OR 1.33, 95% CI 0.75, 2.37). CONCLUSION: These findings suggest that higher AL, particularly when measured using the inflammatory profile-based measure, was associated with poorer HRQOL, namely FWB and FACT-G, among Black breast cancer survivors.
Entities:
Keywords:
Allostatic load; Black women; Breast cancer survivorship; Health-related quality of life; Longitudinal study
Authors: Erik J Rodriquez; Jennifer Livaudais-Toman; Steven E Gregorich; James S Jackson; Anna M Nápoles; Eliseo J Pérez-Stable Journal: Prev Med Date: 2018-02-05 Impact factor: 4.018
Authors: Neha G Goyal; Beverly J Levine; Kimberly J Van Zee; Elizabeth Naftalis; Nancy E Avis Journal: Breast Cancer Res Treat Date: 2018-01-24 Impact factor: 4.872
Authors: Harveshp D Mogal; Marissa Howard-McNatt; Rebecca Dodson; Nora F Fino; Clancy J Clark Journal: Support Care Cancer Date: 2016-12-16 Impact factor: 3.603
Authors: Ashley S Felix; Amy Lehman; Timiya S Nolan; Shawnita Sealy-Jefferson; Khadijah Breathett; Darryl B Hood; Daniel Addison; Cindy M Anderson; Crystal W Cené; Barbara J Warren; Rebecca D Jackson; Karen Patricia Williams Journal: Circ Cardiovasc Qual Outcomes Date: 2019-04
Authors: Electra D Paskett; Catherine M Alfano; Mario A Davidson; Barbara L Andersen; Michelle J Naughton; Aurora Sherman; Paige Green McDonald; Jennifer Hays Journal: Cancer Date: 2008-12-01 Impact factor: 6.860
Authors: Samilia Obeng-Gyasi; Noah Graham; Shaji Kumar; Ju-Whei Lee; Susanna Jacobus; Matthias Weiss; David Cella; Fengmin Zhao; Edward H Ip; Nathaniel O'Connell; Fangxin Hong; Devin J Peipert; IIana F Gareen; Lava R Timsina; Robert Gray; Lynne I Wagner; Ruth C Carlos Journal: Blood Cancer J Date: 2022-04-01 Impact factor: 9.812